The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Open accessAbstract
Spike (S) proteins of coronaviruses, including the coronavirus that causes severe acute respiratory syndrome (SARS), associate with cellular receptors to mediate infection of their target cells. Here we identify a metallopeptidase, angiotensin-converting enzyme 2 (ACE2), isolated from SARS coronavirus (SARS-CoV)-permissive Vero E6 cells, that efficiently binds the S1 domain of the SARS-CoV S protein. We found that a soluble form of ACE2, but not of the related enzyme ACE1, blocked association of the S1 domain with Vero E6 cells. 293T cells transfected with ACE2, but not those transfected with human immunodeficiency virus-1 receptors, formed multinucleated syncytia with cells expressing S protein. Furthermore, SARS-CoV replicated efficiently on ACE2-transfected but not mock-transfected 293T cells. Finally, anti-ACE2 but not anti-ACE1 antibody blocked viral replication on Vero E6 cells. Together our data indicate that ACE2 is a functional receptor for SARS-CoV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, ACE2 (angiotensin-converting enzyme 2) had been identified as the receptor for SARS-CoV 4,5 and SARS-CoV-2.”
From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [5]
In the citing paper
“Study of Zhou et al.4 indicated that the angiotensin-converting enzyme II (ACE2) is likely the cell receptor of 2019-nCoV, which were also the receptor for SARS-CoV and HCoV-NL637,8.”
From High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa (2020) · cites this paper as [7]
In the citing paper
“The cell surface receptor for the CoV-1 and CoV-2 surface spike protein has been identified by affinity-MS to be angiotensin-converting enzyme 2 (ACE2)147”
From A high-stringency blueprint of the human proteome (2020) · cites this paper as [147]
In the citing paper
“As an alternative approach, cellular interaction partners for a single viral protein of interest have also been investigated by in vitro incubation of the viral protein bait with lysates from uninfected permissive cells.”
From Proteomic approaches to uncovering virus–host protein interactions during the progression of viral infection (2016) · cites this paper as [59]
In the citing paper
“while promoted upon ACE2 overexpression in HEK293T cells that are otherwise non-permissive to SARS-CoV.”
From Proteomic approaches to uncovering virus–host protein interactions during the progression of viral infection (2016) · cites this paper as [59]
In the citing paper
“which was further functionally characterized as a functional receptor for SARS-CoV.”
From Proteomic approaches to uncovering virus–host protein interactions during the progression of viral infection (2016) · cites this paper as [59]
In the citing paper
“MS analysis revealed the cellular metallopeptidase angiotensin-converting enzyme 2 (ACE2) as an S1 interaction partner”
From Proteomic approaches to uncovering virus–host protein interactions during the progression of viral infection (2016) · cites this paper as [59]
In the citing paper
“Viral replication was inhibited upon incubation with antibodies against ACE2”
From Proteomic approaches to uncovering virus–host protein interactions during the progression of viral infection (2016) · cites this paper as [59]
In the citing paper
“This interaction requires cleavage of the S protein, likely by the cell surface protease TMPRSS2, although other proteases (such as Cathepsin B and L, CTSB/CTSL) may also be involved (4-6, 22-25).”
From Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia (2020) · cites this paper as [23]
In the citing paper
“CoV-2 — like SARS-CoV — infects cells through interactions between its spike (S) protein and the ACE2 protein on target cells.”
From Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia (2020) · cites this paper as [23]
In the citing paper
“ACE2 is the functional entry receptor for both severe acute respiratory syndrome (SARS) coronaviruses, SARS-CoV (36) and SARS-CoV-2 (37).”
From TCRD and pharos 2021: mining the human proteome for disease biology (2021) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Tg, K., Erdman, D. D., Cs, G., Zaki, Peret, T. C. T., Emery, S. L., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,353
Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R., et al. (2000) · Circulation Research · doi:10.1161/01.res.87.5.e1 · Cited by 2,485
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R. P., Icenogle, J. P., Peñaranda, S., Bankamp, B., Maher, K., Chen, M., et al. (2003) · Science · doi:10.1126/science.1085952 · Cited by 2,477
The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates
Choe, H., Farzan, M., Sun, Y., Sullivan, N. J., Rollins, B. J., Ponath, P. D., Wu, L., Mackay, C. R., LaRosa, G. J., Newman, W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81313-6 · Cited by 2,286
Self-citationA Human Homolog of Angiotensin-converting Enzyme
Tipnis, S. R., Hooper, N. M., Hyde, R., Karran, E. H., Christie, G., & Turner, A. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002615200 · Cited by 2,041
The Genome Sequence of the SARS-Associated Coronavirus
Marra, M. A., Jones, S. J. M., Astell, C. R., Holt, R. A., Brooks-Wilson, A. R., Butterfield, Y. S. N., Khattra, J. S., Asano, J. K., Barber, S., Chan, S. Y., et al. (2003) · Science · doi:10.1126/science.1085953 · Cited by 2,027
Angiotensin-converting enzyme 2 is an essential regulator of heart function
Crackower, M. A., Sarao, R., Oudit, G. Y., Yagil, C., Kozieradzki, I., Scanga, S. E., Oliveira-dos-Santos, A. J., da Costa, J., Zhang, L., Pei, Y., et al. (2002) · Nature · doi:10.1038/nature00786 · Cited by 1,733
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
Vickers, C., Hales, P., Kaushik, V. K., Dick, L. R., Gavin, J. M., Tang, J., Godbout, K., Parsons, T. F., Baronas, E., Hsieh, F., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200581200 · Cited by 1,406
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome
Kuiken, T., Fouchier, R. A. M., Schutten, M., Rimmelzwaan, G. F., van Amerongen, G., van Riel, D. A. J., Laman, J. D., de Jong, T., van Doornum, G., Lim, W. W. L., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13967-0 · Cited by 1,015
Cited by
Sorted by citations
Items 1,001–1,026 of 1,026
He, Y., Zhu, Q., Liu, S., Zhou, Y., Baoan, Y., Li, J., & Jiang, S. (2005) · Virology · doi:10.1016/j.virol.2005.01.034 · Cited by 100
Current Status of COVID-19 Therapies and Drug Repositioning Applications
Altay, O., Mohammadi, E., Lam, S., Turkez, H., Boren, J., Nielsen, J., Uhlen, M., & Mardinoglu, A. (2020) · iScience · doi:10.1016/j.isci.2020.101303 · Cited by 98
Structural Definition of a Neutralization-sensitive Epitope on the MERS-CoV S1-NTD
Wang, N., Rosen, O., Wang, L., Turner, H. L., Stevens, L. J., Corbett, K. S., Bowman, C. A., Pallesen, J., Shi, W., Zhang, Y., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.052 · Cited by 86
Shah, H., Khan, M. S. H., Dhurandhar, N. V., & Hegde, V. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01636-z · Cited by 80
Pentón-Rol, G., Marín-Prida, J., & McCarty, M. F. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210408123807 · Cited by 73
Potential mechanisms of hemorrhagic stroke in elderly COVID-19 patients
Wang, H., Tang, X., Fan, H., Luo, Y., Song, Y., Xu, Y., & Chen, Y. (2020) · Aging · doi:10.18632/aging.103335 · Cited by 69
Coughlin, M., Lou, G., Martinez, O., Masterman, S. K., Olsen, O. A., Moksa, A. A., Farzan, M., Babcook, J. S., & Prabhakar, B. S. (2007) · Virology · doi:10.1016/j.virol.2006.09.029 · Cited by 70
Self-citationImmunological defense of CNS barriers against infections
Ampie, L., & McGavern, D. B. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.012 · Cited by 63
Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective
Hosoki, K., Chakraborty, A., & Sur, S. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.033 · Cited by 63
Adaptation of SARS Coronavirus to Humans
Holmes, K. V. (2005) · Science · doi:10.1126/science.1118817 · Cited by 63
Bai, B., Hu, Q., Hu, H., Zhou, P., Shi, Z., Meng, J., Lu, B., Huang, Y., Mao, P., & Wang, H. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002685 · Cited by 59
Soh, W. T., Liu, Y., Nakayama, E. E., Ono, C., Torii, S., Nakagami, H., Matsuura, Y., Shioda, T., & Arase, H. (2020) · doi:10.1101/2020.11.05.369264 · Cited by 61
Deficiency of Tfh Cells and Germinal Center in Deceased COVID-19 Patients
Duan, Y.-Q., Xia, M.-H., Ren, L., Zhang, Y.-F., Ao, Q.-L., Xu, S.-P., Kuang, D., Liu, Q., Yan, B., Zhou, Y.-W., et al. (2020) · Current Medical Science · doi:10.1007/s11596-020-2225-x · Cited by 59
Renin-angiotensin system in human coronavirus pathogenesis
Wevers, B. A., & Hoek, L. V. D. (2010) · Future Virology · doi:10.2217/fvl.10.4 · Cited by 51
Renin–angiotensin system: Basic and clinical aspects—A general perspective
Vargas Vargas, R. A., Varela Millán, J. M., & Fajardo Bonilla, E. (2022) · Endocrinología, Diabetes y Nutrición (English ed.) · doi:10.1016/j.endien.2022.01.005 · Cited by 51
Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis
Omran, H. M., & Almaliki, M. S. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.06.004 · Cited by 45
Deng, P., Ke, Z., Ying, B., Qiao, B., & Yuan, L. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.07.018 · Cited by 47
Cong, Y., Feng, Y., Ni, H., Zhi, F., Miao, Y., Fang, B., Zhang, L., & Zhang, J. Z. H. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00241 · Cited by 40
Ahmed-Hassan, H., Sisson, B., Shukla, R. K., Wijewantha, Y., Funderburg, N. T., Li, Z., Hayes, D., Demberg, T., & Liyanage, N. P. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01979 · Cited by 47
Biering, S. B., Van Dis, E., Wehri, E., Yamashiro, L. H., Wrynla, X. H., Dugast-Darzacq, C., Graham, T. G. W., Stroumza, J. R., Golovkine, G. R., Roberts, A. W., et al. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00017 · Cited by 28
Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
Günl, F., Mecate-Zambrano, A., Rehländer, S., Hinse, S., Ludwig, S., & Brunotte, L. (2021) · Vaccines · doi:10.3390/vaccines9101052 · Cited by 27
COVID-19 Treatment: The Race Against Time
Aljofan, M., & Gaipov, A. (2020) · Electronic Journal of General Medicine · doi:10.29333/ejgm/7890 · Cited by 27
Attenuation of SARS-CoV-2 infection by losartan in human kidney organoids
Rahmani, W., Chung, H., Sinha, S., Bui-Marinos, M. P., Arora, R., Jaffer, A., Corcoran, J. A., Biernaskie, J., & Chun, J. (2022) · iScience · doi:10.1016/j.isci.2022.103818 · Cited by 25
Devaux, C. A., & Camoin-Jau, L. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1042200 · Cited by 20
Chen, H., Peng, J., Wang, T., Wen, J., Chen, S., Huang, Y., & Zhang, Y. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115370 · Cited by 19
Gangrenous bowel ischemia-a complication of COVID-19: a case report
Swami, G. A., Shinde, S. K., S., H. C., & Asawa, G. (2021) · International Surgery Journal · doi:10.18203/2349-2902.isj20211854 · Cited by 3
Metadata
- Authors
- Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., Choe, H., & Farzan, M.
- Affiliations
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Tufts University (US)
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Choe, Hyeryun
- Farzan, Michael
- ORCID
- Venue
- Nature
- Published
- 2003-11-27
- Volume
- 426
- Issue
- 6965
- Pages
- 450-454
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC7095016
- OpenAlex
- W1966238900
- Cited by
- 5,923
- References
- 32
- Citations by year
- 2026: 74 · 2025: 145 · 2024: 298 · 2023: 448 · 2022: 732 · 2021: 1288 · 2020: 1794 · 2019: 32 · 2018: 30 · 2017: 44 · 2016: 50 · 2015: 49 · 2014: 62 · 2013: 43 · 2012: 50
- FWCI
- 79.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Science Foundation
- National Aeronautics and Space Administration
- Hawaii Community Foundation
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- angiotensin-converting enzyme 2, SARS coronavirus, viral receptor, receptor binding, syncytium formation, viral replication, ACE1, Vero E6 cells, HEK293T cells, antibody inhibition
- MeSH terms
- Angiotensin-Converting Enzyme 2, Animals, Antibodies, Carboxypeptidases, Cell Line, Chlorocebus aethiops, Humans, Peptidyl-Dipeptidase A, Membrane Glycoproteins, Molecular Weight, Protein Binding, Receptors, Virus, Solubility, Transfection, Vero Cells, Viral Envelope Proteins, Virus Replication, Giant Cells, Protein Structure, Tertiary, Severe acute respiratory syndrome-related coronavirus, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
